NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson's (JNJ) subsidiary,
Janssen-Cilag International NV, announced on Friday that the Committee for
Medicinal Products for Human Use or CHMP of the European Medicines Agency has
recommended the approval of Rybrevant also known as amivantamab for the
first-line treatment of adult patients with advanced non-small cell lung cancer
also known as NSCLC.

The CHMP recommendation is based on data from the Phase 3 PAPILLON study, which
demonstrated that Rybrevant plus chemotherapy significantly enhanced
progression-free survival in adult patients compared to chemotherapy alone.

This favorable CHMP opinion positions Rybrevant as a new treatment option and
the first fully human EGFR-MET bispecific antibody for the initial management of
EGFR exon 20 insertion-mutated NSCLC.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX